Language:
English
繁體中文
Help
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
Precision Oncology and Cancer Biomarkers = Issues at Stake and Matters of Concern /
Record Type:
Language materials, printed : Monograph/item
Title/Author:
Precision Oncology and Cancer Biomarkers/ edited by Anne Bremer, Roger Strand.
Reminder of title:
Issues at Stake and Matters of Concern /
other author:
Strand, Roger.
Description:
XIV, 281 p. 1 illus.online resource. :
Contained By:
Springer Nature eBook
Subject:
Health Economics. -
Online resource:
https://doi.org/10.1007/978-3-030-92612-0
ISBN:
9783030926120
Precision Oncology and Cancer Biomarkers = Issues at Stake and Matters of Concern /
Precision Oncology and Cancer Biomarkers
Issues at Stake and Matters of Concern /[electronic resource] :edited by Anne Bremer, Roger Strand. - 1st ed. 2022. - XIV, 281 p. 1 illus.online resource. - Human Perspectives in Health Sciences and Technology,52661-8923 ;. - Human Perspectives in Health Sciences and Technology,1.
Introduction (Anne Bremer and Roger Strand) -- Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen) -- Chapter 2. Cancer biomarkers from a patient’s perspective (Karen Gissum) -- Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås) -- Chapter 4. HER2: an apparently ‘simple’ biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen) -- Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti) -- Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand) -- Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg) -- Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand) -- Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck) -- Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand) -- Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns) -- Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang) -- Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal) -- Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).
Open Access
This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research. This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisation of care? What are the patients’ experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists.
ISBN: 9783030926120
Standard No.: 10.1007/978-3-030-92612-0doiSubjects--Topical Terms:
786205
Health Economics.
LC Class. No.: R723-723.7
Dewey Class. No.: 610.1
Precision Oncology and Cancer Biomarkers = Issues at Stake and Matters of Concern /
LDR
:04471nam a22004575i 4500
001
1091503
003
DE-He213
005
20220329035514.0
007
cr nn 008mamaa
008
221228s2022 sz | s |||| 0|eng d
020
$a
9783030926120
$9
978-3-030-92612-0
024
7
$a
10.1007/978-3-030-92612-0
$2
doi
035
$a
978-3-030-92612-0
050
4
$a
R723-723.7
072
7
$a
HP
$2
bicssc
072
7
$a
MBDC
$2
bicssc
072
7
$a
MED050000
$2
bisacsh
072
7
$a
QD
$2
thema
072
7
$a
MBDC
$2
thema
082
0 4
$a
610.1
$2
23
245
1 0
$a
Precision Oncology and Cancer Biomarkers
$h
[electronic resource] :
$b
Issues at Stake and Matters of Concern /
$c
edited by Anne Bremer, Roger Strand.
250
$a
1st ed. 2022.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2022.
300
$a
XIV, 281 p. 1 illus.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
490
1
$a
Human Perspectives in Health Sciences and Technology,
$x
2661-8923 ;
$v
5
505
0
$a
Introduction (Anne Bremer and Roger Strand) -- Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen) -- Chapter 2. Cancer biomarkers from a patient’s perspective (Karen Gissum) -- Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås) -- Chapter 4. HER2: an apparently ‘simple’ biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen) -- Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti) -- Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand) -- Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg) -- Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand) -- Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck) -- Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand) -- Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns) -- Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang) -- Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal) -- Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).
506
0
$a
Open Access
520
$a
This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research. This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisation of care? What are the patients’ experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists.
650
2 4
$a
Health Economics.
$3
786205
650
2 4
$a
Public Health.
$3
592982
650
2 4
$a
Cancer Biology.
$3
1388882
650
1 4
$a
Philosophy of Medicine.
$3
671737
650
0
$a
Medical economics.
$3
559095
650
0
$a
Public health.
$3
560998
650
0
$a
Cancer.
$3
581034
650
0
$a
Bioethics.
$3
567376
650
0
$a
Medicine—Philosophy.
$3
1253490
700
1
$a
Strand, Roger.
$e
editor.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1399104
700
1
$a
Bremer, Anne.
$e
editor.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1399103
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783030926113
776
0 8
$i
Printed edition:
$z
9783030926137
776
0 8
$i
Printed edition:
$z
9783030926144
830
0
$a
Human Perspectives in Health Sciences and Technology,
$x
2661-8915 ;
$v
1
$3
1316807
856
4 0
$u
https://doi.org/10.1007/978-3-030-92612-0
912
$a
ZDB-2-REP
912
$a
ZDB-2-SXPR
912
$a
ZDB-2-SOB
950
$a
Religion and Philosophy (SpringerNature-41175)
950
$a
Philosophy and Religion (R0) (SpringerNature-43725)
based on 0 review(s)
Multimedia
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login